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Background.Westudiedtheeﬀectoffastinductionofcardiacarrestwithdenosineonmyocardialbaxandbcl-2expression.Methods
andResults.40elective CABGpatientswere allocated intotwogroups.Theadenosinegroup(n = 20)received 250μg/kgadenosine
into the aortic root followed by blood potassium cardioplegia. The control group received potassium cardioplegia in blood. Bcl-2
and bax were measured. Bax was reduced in the postoperative biopsies (1.38 versus 0.47, P = .002) in the control group. Bcl-2
showed a reducing tendency (0.14 versus 0.085, P = .07). After the adenosine treatment, the expression of both bax (0.52 versus
0.59, P = .4) and bcl-2 (0.104 versus 0.107, P = .4) remained unaltered after the operation. Conclusion. Open heart surgery is
associated with rapid reduction in the expression of apoptosis regulating genes bax and bcl-2. Fast Adenosine induction abolished
changes in their expression.
Copyright © 2009 Ahmed Shalaby et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Apoptosis has been considered as one of the mechanisms
of cell loss during ischemia/reperfusion (I/R) injury [1–3].
The presence of cardiomyocyte apoptosis (CA) is evident
early after cardioplegic arrest and open heart surgery both
in animal models and humans [4, 5]. The mechanism
underlying I/R-induced apoptosis as well as its clinical
signiﬁcance during open heart surgery remains incompletely
elucidated [4]. However, recent studies demonstrate that
cardioplegic arrest immediately activates the myocardial
apoptosis signal pathway.
Myocardial upregulation of the proapoptotic gene bax
and reduction of both bcl-2 and bcl-2/bax ratios are predis-
posing the cardiomyocytes to apoptosis [6, 7]. Their changes
in response to transient ischemia have been described in
experimental models and in the border zones of human
myocardial infarction. Furthermore, inhibition of apoptosis
during reperfusion is associated with reduction in infarction
size, improvement in regional contractile and vascular
endothelial functions, as well as augmentation in myocardial
blood ﬂow [8–14].
Injection of adenosine into the aortic root followed by
blood cardioplegia solution after cross-clamping, produces
signiﬁcantly faster cardiac standstill in patients with severe
coronary artery disease [15, 16]. Adenosine attenuates post-
cardioplegic dysfunction in severely injured hearts through
the operation of receptor-mediated mechanisms [17–20]. In
an experimental animal model, adenosine inhibits apoptosis
via modulation of antiapoptotic bcl-2 and proapoptotic bax
genes and neutrophil accumulation, primarily mediated by
an adenosine A2a receptor [21–23].
The main motive behind our present study is based
on the previous ﬁndings [22, 23] representing the fact
that apoptosis represents a potentially preventable form of
cell death owing to its active nature, specially that these
ﬁndings may have important clinical implications as new
cardioprotective treatment strategies are developed.2 Cardiology Research and Practice
The aim of this study was to determine whether cardiac
surgery using cardiopulmonary bypass (CPB) is associated
with changes in the expression of apoptosis-regulating genes
bax and bcl-2 in humans. We also studied whether more
rapid induction of myocardial arrest by a single bolus injec-
tion of adenosine followed by potassium blood cardioplegia
modiﬁes their expression. We hypothesized that analysis of
bax and bcl-2 changes in genes expression might serve a
marker of myocardial injury and success of cardioprotection
early after cardiac surgery with cardioplegic arrest.
2.MaterialandMethods
2.1.PatientSelection. Themainc ohortofthisstud yincluded
40 patients who were scheduled for an elective CABG
procedure using on-pump CPB technique. The exclusion
criteria were diabetic patients with sulfonylurea medication,
unstable angina, recent myocardial infarction within the last
month, redo cardiac operation, preoperative diagnosis of
asthma, chronic obstructive pulmonary disease; the patients
did not have a history of chronic renal or hepatic diseases,
and their values of creatinine (50–90 female, 60–100 male,
115mmol/L) and aP-TT-INR (International normalised
ratio; 0.9–1.2 ) were within normal range. Patients with
poor left ventricular function (ejection fraction EF ≤ 30),
valvular disease, and those receiving corticosteroids were
also considered not eligible. After institutional approval
by the Ethics Committee of Tampere University Hospital,
the protocol for this prospective randomized, double blind,
placebo-controlled study was reviewed by National Agency
for Medicines, Finland. All 40 patients gave their informed
consent.
In our previous publication [24] we had collected the
data from the same study cohort but in the present report we
have added more end points based on more comprehensive
analysis in order to better understand the mechanisms of
cardioplegic arrest.
2.2. Anaesthesia. A radial artery line and a pulmonary
artery catheter were inserted for haemodynamic monitoring.
Anaesthesia was induced with propofol (0.5–1.0mg/kg),
sufentanil (0.6–0.8μg/kg), and cisatracurium. Sufentanil
infusion was continued with a rate of 0.03–0.05μg/kg/min.
Sevoﬂurane was used as the main anaesthetic agent through-
out the operation, and also provided during the cardiopul-
monary perfusion with a vaporiser attached to the fresh gas
inlet.
2.3. Operative and Perfusion Techniques. The surgical tech-
niques were standardized in all cases, including median
sternotomy, and one internal thoracic artery, along with
one to four peripheral veins from the lower extremities
harvested in each case. Left radial artery was harvested
whenever indicated. CPB was established with standard
cannulation technique, using mild hypothermia (35◦C)
with nonpulsative ﬂow with a membrane oxygenator. The
circuit was primed with 1500mL of Ringer’s acetate. The
proximal anastomoses were constructed during a single
cross-clamping period.
2.4. Cardioplegia and Adenosine Administration. Patients
randomization was between January 2006 and May 2007.
Patients were allocated into two groups. In the adenosine
group, 20 patients received 250μg/kg adenosine into the
aortic root just after cross-clamping. This dose was chosen
in view of a pilot study to be the lowest eﬀective dose to
stop the myocardium. The plan is to use Adenosine as a
single bolus dose to allow the evaluation of adenosine not
only as a pretreatment during the reperfusion but also as a
maintenance dose of myocardial protection during ischemia
and reperfusion.
20 patients in the control group received normal saline
as placebo. All patients received standard blood cardioplegia
delivered through antegrade route. The basal CP concen-
trations were identical in both groups, except for the study
medication. Concentrations of potassium and magnesium
dependonthemixing ratioofcardioplegia rollers.Ratio1 : 4
is used for the induction, 1 : 8 for the subsequent infusions
and also for the warm terminal infusion.
Total volume of cardioplegia (CP) was not recorded.
Cardioplegia was administered by means of time, pressure,
and ﬂow (according to the guidelines by Dr. Buckberg).
CP was infused via antegrade route with pressure of 60–
80mmHg. Maximal ﬂow was 300mL/min. Duration of the
induction infusion was three minutes. Additional infusions
after each distal anastomosis were for one minute, and the
ﬁnal warm infusion was given for three minutes. The eﬀect
of adenosine is known to be dependent on the temperature
[2]. Therefore, the ﬁrst cardioplegia infusion was given at
normothermia (36-37
◦C) until asystole of the heart was
acquired, or at least for one minute if asystole was acquired
sooner.Thereafter,thecoolingdevicesettingwas10
◦Cwhic h
yielded CP of 12-13
◦C. Subsequent one-minute antegrade
cardioplegia infusions were administered after completion
of each distal anastomosis. Final warm CP was given at
normothermia; that is, 36-37
◦C.
2.5. Tissue Harvesting. From each patient, we harvested two
samples from the right atrium at two diﬀerent times. The
ﬁrst one was obtained before cross-clamping as the baseline
biopsy and the second from the same location just before
CPB was discontinued. Myocardial samples (5–10 × 3mm)
were immediately frozen in liquid nitrogen for assessment of
gene expression.
Two samples of left ventricular apex were harvested
in both groups. The ﬁrst sample was taken immediately
after CPB was established by oblique introduction of Tru-
Cut needle (PRECISA TM 14G X 150mm) into the left
ventricle apical wall. The second sample was taken from
the same location by the same needle before weaning
from CPB. The puncture sites were secured with small 4-0
prolene(Ethicon)stitchesevenwhennobleedingoccurred.
Myocardial tissue (5–10 × 3mm) was immediately frozen in
liquid nitrogen for histological studies.
2.6. Total RNA Extraction and Complementary DNA Syn-
thesis. Atria samples were homogenized and total RNA was
extracted with Trizol reagent (Invitrogen) according to
manufacturer’s instructions. The RNA concentration wasCardiology Research and Practice 3
determined using spectrophotometry. Total RNA (1μg)
from each sample was incubated with equal amount of
random hexamers (PromegaTM)a t7 0 ◦Cf o r1 0m i n u t e s
and then cooled on ice for 5 minutes. Complementary
DNA (cDNA) was synthesized in a mixture containing M-
MLVReverseTranscriptaseRNaseHMinus-enzyme(200U),
Recombinant RNasin Ribonuclease Inhibitor (40U), dNTP
mix (25mM each), M-MLV RT 5x buﬀer, and Nuclease-
free water (all purchased from Promega Corp. WI, USA).
Mixtures were incubated at room temperature for the initial
10 minutes, then at 50◦C for the ﬁnal 50 minutes. Finally, the
reaction was inactivated by heating for 5 minutes at 95◦C.
2.7. Primers and Probes. Sequences of the oligonucleotide
primers and probes used in real-time quantitative reverse
transcriptase polymerase chain reaction (RT-PCR) assay
were the same that used for bax and bcl-2 [25] (Sequence
detection primer, Applied Biosystems Inc, CA, USA) and
probes (TaqMan TAMRATM Probe, Applied Biosystems)
used in real-time quantitative reverse transcriptase poly-
merase chain reaction (RT-PCR) assay. In order to prevent
the ampliﬁcation of contaminating genomic DNA, primer
pairs were located in diﬀerent exons. Housekeeping gene 18S
rRNA was used as an endogenous control (The TaqMan
Ribosomal RNA Control Reagents, Applied Biosystems).
2.8. RT-PCR Assay. The quantitative real-time RT-PCR
was performed using Applied Biosystems 7500 RT-PCR
system and Taqman-based chemistry. The PCR solution-
composed of 5ng cDNA, forward and reverse primers
(400nM), speciﬁc probe (100nM), and TaqMan Universal
PCR Master Mix. Primer and probe concentrations for 18S
were 50nM and 200nM, respectively. After incubation at
50◦C for 2 minutes and denaturing at 95◦Cf o r1 0m i n u t e s ,
PCR was carried out, 50 cycles of 95◦C for 15 seconds and
60◦C for 1 minute. All RT-PCR reactions were run as a
duplicate.
2.9. Quantiﬁcation of Gene Expression. Quantiﬁcation of
gene expression was carried out by using relative standard
curve method. Brieﬂy, standard curves for each plate were
generated using serial dilutions of cDNA synthesized from
h u m a nt o n s i lt i s s u eR N A .T h ea m o u n t so fb o t ht a r g e ta n d
endogenous control cDNA in each sample were calculated
relative to the standards. To eliminate the variation of total
cDNA quantity in each sample, the results are expressed as a
ratio of the target gene to the endogenous control.
2.10. Assessment of Apoptosis in Left Ventricular Tissue.
Apoptosis was detected using the terminal transferase
mediated ddUTP nick end-labeling (TUNEL) assay, as
previously described [26, 27]. In brief, paraﬃn-embedded
myocardial sections were heated in sodium citrate solution
and digested with proteinase-K to expose DNA. The DNA
strand breaks were then labeled using terminal transferase
with digoxigenin-conjugated ddUTP and visualized using
alkaline phosphatase immunohistochemistry (IHC). To con-
ﬁrm optimal sensitivity of the assay, it was standardized
with the use of serial sections treated with DNase I to
induce enzymatic DNA fragmentation (positive control of
apoptosis). The apoptotic rate was deﬁned as the positive
TUNEL cardiomyocytes per ﬁeld, and expressed as % of
cardiomyocytes.
2.11. Statistical Analyses. Statistical analysis was performed
using SPSS for Windows software, version 9.0 (SPSS;
Chicago IL, USA). The Mann-Whitney U Test was used
to distinguish demographic diﬀerences in means between
the groups. Continuous variables were analyzed by analysis
of variance (ANOVA) for repeated measures. Logarithmic
transformation, median and quarter analysis methods were
used when the variables were not normally distributed.
Statistical signiﬁcance was attributed to P value <.05.
3. Results
3.1. Patient Characteristics
Demographic and Basic Clinical Data. The study cohort
included40patientsbetweentheagesof46and73years,90%
of them were male patients (Table 1). Twenty patients were
given adenosine and the others served as controls. All the
patients in both groups completed the study protocol. There
were no adverse eﬀects related to adenosine. There were no
adversepostoperativecomplicationsinanyofthe40patients.
All the patients survived the operation and were discharged
from the hospital. There were no adverse eﬀects related to
adenosine. There was no signiﬁcant diﬀerence in the baseline
characteristicsofthepatientsbetweenstudygroupsasshown
in Table 1.
As shown in Table 2 and Figure 1, in the control group,
expression of bax gene was signiﬁcantly reduced in the
postoperative samples as compared with the preoperative
samples (P = .002). Expression of bcl-2 showed a similar
reduction tendency (P = .07). However, in contrast to the
control group, expression of both bax and bcl-2 remained
unaltered before and after the operation in the adenosine
treatment group (P = .45 and .47). There were no signiﬁcant
diﬀerences in the level of bax/bcl-2 ratio expression in either
pre- or postoperative samples in the control and adenosine
groups.
As shown in Table 2, (the ventricular samples were used
todetecttheapoptoticindexandthenpatientswereallocated
into subgroups accordingly to TUNEL positive and negative,
meanwhile the atria samples were used to detect the gene
expression of apoptosis) there were no signiﬁcant diﬀerences
in either expression or bax/bcl-2 ratio between patients who
had or had not TUNEL positive cardiomyocytes in the left
ventricular tissue samples. Neither was there correlation
between gene expression nor the amount of TUNEL positive
myocytes. However, there was a tendency towards lower bcl-
2 expression and higher bax expression in patients with
TUNEL positive myocytes as shown in Table 2.
Values are presented as median values and standard
deviation. “Before” refers to before cross-clamp application
and “After” refers to after cross-clamp removal and just
before CPB discontinuation.4 Cardiology Research and Practice
Table 1: Base line Patient Characteristics and operative data.
Adenosine (n = 20) Control (n = 20)
Age (years)∗ 63.4 ±6.86 5 .5 ±7.3


















No of Grafted 33
vessels∗
CKMB∗ 33
CBP time 94 ±25 91 ±16
Ischemic time 79 ±26 72 ±18
Weaning time 15 ±6.41 9 ±8
∗Figurespresentthemeanvalue,CKMBindicatespreoperativevaluetheday
before the operation.
†Vessels classiﬁed regarding to the site of lesion and percentage of stenosis
and according to the most recent coronary angiography, which is used to
make the decision to operate the patient. Figures present the number of
vessels aﬀected in each category.
4. Discussion
We found a decrease in apoptosis regulating genes in
right atria samples obtained immediately after reperfusion
compared to preischemic samples in patients undergoing
CABG. Interestingly, expression remained stable in patients
randomized to adenosine treatment during cardioplegia.
Also, in the adenosine group, the bax/bcl-2 ratio decreased
more than in the control group, although the decrease was
not statistically signiﬁcant.
Previously, in a canine model, adenosine reduced apop-
tosis induced by I/R injury. This reduction was associated
with enhanced expression of antiapoptotic bcl2 genes.
Adenosine also reduced expression of proapoptotic bax
gene in the peri-infarct myocardium [21]. Our results are
consistent with the previous in that the level of antiapoptotic
bcl-2 expression decreased after ischemia in the control
group while the adenosine treatment prevented this down-
regulation [21]. In contrast to the previous study, we found
that also the expression of proapoptotic bax was reduced
in the control group while its expression remained stable











After Before After Before
Bax 18s P = (.002 & .45) Bcl2 18s P = (.07 & .47)
Control
Adenosine
Figure 1: Baseline versus the postoperative expressions of bax and
bcl2 in adenosine treated and the control groups. Gene expression
is normalized to the same endogenous gene. Before and After refer
to the timing of taking the biopsies (Before; before cross clamp
application and After; after cross clamp removal and just before
CPB discontinuation).
short time reperfusion (versus 6 hours of reperfusion in the
earlier study). Cardioplegic protection during ischemia may
suppress proapoptotic signaling, and RNA expression may
not directly reﬂect protein levels that were measured in the
earlier study.
In parallel with the observed changes in the expression
of apoptosis-regulated genes, the amount of apoptotic
cardiomyocytes as detected with the TUNEL-assay in the left
ventricular samples of the patients appeared to be reduced
in the adenosine treated group as reported earlier [28].
However, due to small percentage of apoptotic cells and
high variation in the results, this change was not statis-
tically signiﬁcant. Detection of apoptotic cardiomyocytes
is methodologically challenging, because the appearance
of DNA fragmentation is a late feature of the apoptotic
process and, therefore, TUNEL method may detect only
small fraction of eventually apoptotic cells when the samples
are taken very shortly after reperfusion [29]. Therefore, we
hypothesized that measurement of changes in apoptosis-
regulating genes could serve as an early marker of the
severity of ischemic myocardial injury as well as provide
means to study eﬀects of cardioprotective interventions in
tissue biopsies obtained in the early reperfusion period.
Although there was a diﬀerence between the control and the
adenosine treated groups, there are several doubts in this
approach. First, the variation between individual patients
in the baseline and postoperative expression was high since
this is a clinical study and there is always something cannot
be controlled in small powered trial. Second, we could not
demonstrate relationships either between gene expression
and the amount of apoptosis or the amount TUNEL positive
cardiomyocytes. Third, the results need to be interpreted
cautiously due to the complex interplay between pro- and
antiapoptotic regulators.Cardiology Research and Practice 5
Table 2: TUNEL positive and negative subgroups (of the ventricular samples) in both the adenosine and control groups in correlation with
the changes of apoptosis-regulating genes in the atria samples.
bax bcl-2 bax/bcl-2
Group Subgroup Before After Before After Before After
TUNEL negative 0.47 ±0.83 0.53 ±1.17 0.1 ±0.07 0.15 ±0.74 .97 ±8.53 .88 ± 5.6
Adenosine TUNEL positive 0.91 ±3.30 .35 ±2.40 .29 ±1.70 .08 ±1.32 .4 ±2.45 .1 ±5.1
Total group 0.52 ±16.50 .59 ±2.36 0.104 ±0.91 0.107 ±0.79 8.8 ±13.67 5.1 ±15.75
TUNEL negative 1.4 ± 20.50 .44 ±1.20 .28 ±2.50 .09 ±0.36 .02 ±5.34 .38 ±13.5
Control TUNEL positive 0.92 ±4.50 .64 ±0.90 .23 ±0.50 .12 ±0.25 .21 ±5.27 .57 ± 7.5
Total group 1.37 ± 13.07 0.47 ±1.04 0.14 ±1.64 0.08 ±0.25 6.6 ±15.86 .4 ±20.9
Therefore, further methodological validation and devel-
opment is still needed. Future studies should explore at least
the use of other genes as potential markers as well as optimal
timing of tissue sampling.
In the overall picture, as expressed in Table 2, the present
study has the value to address the facts that CPB (or aortic
cross-clamping) has a signiﬁcant eﬀect on myocardial injury
duetothesigniﬁcantamountofapoptoticcellsdetectedafter
weaningfromthebypass.Fastinductionofmyocardialarrest
could be obtained by intraaortic injection of adenosine. This
injection was able to modulate the expression of apoptotic
genes decreasing the occurrence of apoptosis signiﬁcantly.
Some previous studies which were focusing on the eﬀect
of fast adenosine induction of myocardial arrest showed
the postoperative clinical improvement in this group of
patients [20]. As we reported before [24], we could not
demonstrate this clinical eﬀect in our setting but this ﬁnding
doesnotexcludetheeﬀectofadenosinetodecreaseapoptosis
in such patients. Such eﬀect cannot be overlooked during
the trials to improve the quality of myocardial protection.
These results should be conﬁrmed in more highly powered
studies, possibly with more critical patient cohort. Changing
the timing of adenosine administration during reperfusion
should be considered for further evaluation.
In conclusion, cardioplegic arrest during CABG surgery
results in changes in apoptosis-regulating genes. The change
is detectable in myocardial tissue samples obtained very
early after reperfusion and therefore, this method may allow
assessment of the quality of myocardial protection.
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